Status:
COMPLETED
A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme
Lead Sponsor:
AstraZeneca
Conditions:
Glioblastoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of the study is to determine the efficacy of gefitinib (IressaTM) in combination with radiotherapy on patients with glioblastoma multiforme.
Eligibility Criteria
Inclusion
- Signed informed consent
- histologically-or cytologically-confirmed glioblastoma multiforme
- age 18 years or older
Exclusion
- Have had prior radiation therapy, immunotherapy, gene therapy and/or chemotherapy for the glioblastoma
- co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
- known severe hypersensitivity to ZD1839 or any of the excipients of this product.
Key Trial Info
Start Date :
February 1 2003
Trial Type :
INTERVENTIONAL
End Date :
March 1 2006
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00238797
Start Date
February 1 2003
End Date
March 1 2006
Last Update
January 21 2011
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Linköping, Sweden
2
Research Site
Stockholm, Sweden
3
Research Site
Umeå, Sweden